Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 76364, held by Taro Pharm Inds. Hydrocortisone Butyrate.
As of Nov 16, 2026, ANDA 76364 (Hydrocortisone Butyrate), held by Taro Pharm Inds, was first approved by FDA on Jan 14, 2004, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Hydrocortisone Butyrate Ointment, 0.1% and Hydrocortisone Butyrate Cream USP, 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Hydrocortisone Butyrate Topical Solution, 0.1% is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 14, 2004 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrocortisone Butyrate0.1% · solution;topical | Hydrocortisone Butyrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters